Giraudo Bryan
SEC Form 4 insider trading activity
Giraudo Bryan has filed 4 SEC Form 4 filings (9 transaction rows) across 2 companies, including PTGX, GOSS, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: May 12, 2026.
On the most recent filing, Giraudo Bryan is listed as Director at Protagonist Therapeutics, Inc. Inside the rolling window, Giraudo Bryan reported no open-market purchases and 2 open-market sales totaling $5.9M in PTGX. The largest disclosed transaction in the window is a sale of 48,000 PTGX shares on May 7, 2026, worth $4.8M.
Companies traded
Other insiders at PTGX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.9M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Giraudo Bryan made?
Giraudo Bryan has filed 4 SEC Form 4 filings (9 transaction rows) across 2 companies, including PTGX, GOSS since 2025.
Which companies does Giraudo Bryan trade?
Giraudo Bryan has filed SEC Form 4 disclosures for 2 companies, including PTGX, GOSS.
When was Giraudo Bryan's most recent SEC Form 4 filing?
Giraudo Bryan's most recent SEC Form 4 filing on Tracefour is dated May 12, 2026.
What is Giraudo Bryan's total buy and sell value in the current window?
Inside the rolling retention window, Giraudo Bryan bought $0 and sold $5.9M based on SEC Form 4 filings.
What was Giraudo Bryan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 48,000 PTGX shares on 2026-05-07, worth $4.8M, per SEC Form 4 filings.